Metformin controlled release - Bristol-Myers Squibb/Merck

Drug Profile

Metformin controlled release - Bristol-Myers Squibb/Merck

Alternative Names: Glucophage XR; Metformin extended release - Bristol-Myers Squibb; Metformin extended release - Merck; Metformin XR - Bristol-Myers Squibb

Latest Information Update: 04 Nov 2014

Price : $50

At a glance

  • Originator Merck & Co
  • Developer Bristol-Myers Squibb; Merck & Co; Zuellig Pharma
  • Class Antihyperglycaemics; Biguanides; Small molecules
  • Mechanism of Action AMP activated protein kinase stimulants; Gluconeogenesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Type 2 diabetes mellitus

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 26 Sep 2014 Launched for Type-2 diabetes mellitus in Germany (PO)
  • 01 Dec 2004 Launched for Type-2 diabetes mellitus in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top